Blood Glucose Monitoring Data Should Be Reported in Detail When Studies About Efficacy of Continuous Glucose Monitoring Systems Are Published.
Stefan PleusLutz HeinemannGuido FreckmannPublished in: Journal of diabetes science and technology (2018)
Recently, two clinical trials about a "sensor-based flash glucose monitoring system" and its efficacy in reducing time in hypoglycemia were published. Interestingly, patients spent more time at low glucose concentrations in these studies than in other studies related to the efficacy of real-time continuous glucose monitoring (rtCGM). Although it is possible that the study populations differed from those in other studies, another potential explanation is that the CGM system used in these two studies had a negative glucose measurement bias. Such a negative bias was reported in recent literature, suggesting that the CGM system may inaccurately indicate hypoglycemia. Reporting blood glucose monitoring data would help to interpret the CGM data at least in the context of time spent in various glucose ranges as a parameter with which quality of diabetes therapy is measured.
Keyphrases
- blood glucose
- glycemic control
- type diabetes
- case control
- clinical trial
- electronic health record
- end stage renal disease
- cardiovascular disease
- systematic review
- ejection fraction
- newly diagnosed
- stem cells
- risk assessment
- chronic kidney disease
- prognostic factors
- deep learning
- mesenchymal stem cells
- peritoneal dialysis
- bone marrow
- quality improvement
- phase iii
- drug induced
- genetic diversity